A. Wells (London, United Kingdom), V. Cottin (Lyon, France)
Does anti-acid treatment influence disease progression in SSc-ILD ? data from the German SSc-network
M. Kreuter (Heidelberg, Germany), F. Bonella (Essen, Germany), N. Blank (Heidelberg, Germany), E. Siegert (Berlin, Germany), J. Henes (Tübingen, Germany), M. Worm (Berlin, Germany), C. Sunderkoetter (Muenster, Germany), M. Schmalzing (Wuerzburg, Germany), A. Kreuter (Oberhausen, Germany), C. Guenther (Dresden, Germany), L. Susok (Bochum, Germany), G. Zeidler (Treuenbrietzen, Germany), I. Koetter (Hamburg, Germany), U. Mueller-Ladner (Bad Nauheim, Germany), T. Krieg (Cologne, Germany), A. Juche (Berlin, Germany), T. Schmeiser (Wuppertal, Germany), G. Riemekasten (Luebeck, Germany), E. Aberer (Graz, Austria), N. Gaebelein-Wissing (Wuppertal, Germany), J. Distler (Erlangen, Germany), M. Sárdy (Munich, Germany), C. Pfeiffer (Ulm, Germany), K. Kuhr (Cologne, Germany), H. Lorenz (Heidelberg, Germany), P. Moinzadeh (Cologne, Germany), N. Hunzelmann (Cologne, Germany)
|    |
Minor salivary gland biopsy and dry ocular tests to detect occult Sjögren Syndrome in patients with interstitial pneumonia with autoimmune features
S. Auteri (Buenos Aires, Argentina), C. Garbarino (Buenos Aires, Argentina), M. Blanco (Buenos Aires, Argentina), M. Alberti (Buenos Aires, Argentina), F. Paulin (Buenos Aires, Argentina), M. Fernandez (Buenos Aires, Argentina), G. Carballo (Buenos Aires, Argentina), M. Rayá (Buenos Aires, Argentina), G. Guman (Buenos Aires, Argentina), F. Caro (Buenos Aires, Argentina)
| |
IGFBP-2: a new pathway in systemic sclerosis associated interstitial lung disease
F. Gester (Liege, Belgium), M. Henket (Liege, Belgium), D. Deseny (Liege, Belgium), C. Moermans (Liege, Belgium), B. André (Liege, Belgium), M. Malaise (Liege, Belgium), R. Louis (Liege, Belgium), J. Guiot (Liege, Belgium)
| |
Disease course and outcome of progressive interstitial lung disease in systemic sclerosis
A. Hoffmann-Vold (Oslo, Norway), Y. Allanore (Paris, France), M. Alves (Ingelheim am Rhein, Germany), N. Graf (Winterthur , Switzerland), P. Airò (Brescia, Italy), L. Ananyeva (Moscow, Russian Federation), L. Czirják (Pécs, Hungary), S. Guiducci (Florence, Italy), E. Hachulla (Lille, France), M. Li (Beijing, China), C. Mihai (Zurich, Switzerland), G. Riemekasten (Lübeck, Germany), P. Sfikakis (Athens, Greece), G. Valentini (Napoli, Italy), O. Kowal-Bielecka (Bialystok, Poland), O. Distler (Zurich, Switzerland)
|  |
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial
T. Maher (London , United Kingdom), O. Distler (Zurich , Switzerland), A. Azuma (Tokyo , Japan), A. Fischer (Denver, Colorado, United States of America), K. Highland (Cleveland, Ohio, United States of America), M. Kuwana (Tokyo , Japan), M. Mayes (Houston, Texas, United States of America), D. Wachtlin (Ingelheim am Rhein, Germany), M. Alves (Ingelheim am Rhein , Germany), M. Gahlemann (Basel , Switzerland), S. Stowasser (Ingelheim am Rhein, Germany), G. Raghu (Seattle, United States of America)
| |
Clinical utility of CCL15 as a prognostic biomarker for hypersensitivity pneumonitis
M. Watanabe (Kochi, Japan), Y. Horimasu (Hiroshima, Japan), H. Iwamoto (Hiroshima, Japan), K. Yamaguchi (Hiroshima, Japan), S. Sakamoto (Hiroshima, Japan), T. Masuda (Hiroshima, Japan), T. Nakashima (Hiroshima, Japan), S. Miyamoto (Hiroshima, Japan), S. Ohshimo (Hiroshima, Japan), K. Fujitaka (Hiroshima, Japan), H. Hamada (Hiroshima, Japan), N. Kohno (Hiroshima, Japan), N. Hattori (Hiroshima, Japan)
| |
Impact of BAL lymphocytosis and honeycombing presence on corticosteroid treatment effect in Fibrotic Hypersensitivity Pneumonitis
L. De Sadeleer (Leuven, Belgium), F. Hermans (Leuven, Belgium), E. De Dycker (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), J. Verschakelen (Leuven, Belgium), E. Verbeken (Leuven, Belgium), G. Verleden (Leuven, Belgium), S. Verleden (Leuven, Belgium), W. Wuyts (Leuven, Belgium)
| |